Fanny Jaulin

Dr. Fanny Jaulin, CEO of Orakl Oncology, brings 20 years of expertise in cancer cell biology and precision oncology. Motivated by a deep commitment to turning fundamental discoveries into clinical impact, she first established her academic lab at Gustave Roussy to bridge basic biology with real-world therapeutic applications. Through interdisciplinary collaborations with clinicians, engineers, and biologists — across both academia and industry — she spearheaded translational initiatives using tumor avatars to advance personalized cancer care. Driven by the ambition to build transformative solutions and deliver on the promise of precision medicine for patients, Dr. Jaulin launched Orakl Oncology, a Gustave Roussy spin-off, in 2023. Orakl’s mission is to disrupt oncology drug development with a first-in-class, AI-native predictive platform. By integrating patient-derived biology, advanced AI, and real-world clinical data, Orakl uncovers novel drug targets, predicts patient responses, and